Charlotte A. Leseman

Charlotte A. Leseman

Auto-generated profile, based on publicly available information

Charlotte A. Leseman

Department of Surgery, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in BJS Open
Verified
Journal Article
Open access
CLCharlotte A Leseman
Charlotte A Leseman
CVCharlotte L van Veldhuisen
Charlotte L van Veldhuisen
IRIngmar F Rompen
Ingmar F Rompen
SBStefan A Bouwense
Stefan A Bouwense
KBKoop Bosscha
Koop Bosscha
MBMarc G. Besselink
Marc G. Besselink

3 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
CVCl van Veldhuisen
Cl van Veldhuisen
CLCharlotte Leseman
Charlotte Leseman
FRFleur de Rijk
Fleur de Rijk
JMJoana Marques-Antunes
Joana Marques-Antunes
FAFabio Ausania
Fabio Ausania
MBMarc G. Besselink
Marc G. Besselink
Background: Current guidelines provide recommendations for morphology-based surgery in patients with symptomatic chronic pancreatitis (CP). International studies evaluating the use and impact of these guidelines across Europe are lacking.Methods: Post-hoc analysis in the prospective multicenter international ESCOPA study, including patients undergoing surgery for CP in 22 centers in 13 countries (June 2021 - November 2022), with a 6-month follow-up. Patients were stratified into morphological subtypes: ‘isolated dilated main pancreatic duct (MPD)’, ‘isolated enlarged pancreatic head (PH)’, ‘combined dilated MPD and enlarged PH’, and ‘small duct disease’. Treatment was based on the European HaPanEU and International IAP-APA-JPS-EPC guidelines. Primary outcomes were 90-day major morbidity, mortality, and pain relief at 6 months. Practice variation was assessed, including a case-based survey.Results: Overall, 207 patients underwent surgery for symptomatic CP with 1.4% 90-day mortality and 72.6% pain relief. Per morphological subtype, the type of surgery varied widely: mostly duodenum-preserving pancreatic head resections (DPPHR) for ‘combined dilated MPD and enlarged PH’ (22/47, 46.8%, p=0.016); and mostly formal pancreatectomy for both ‘isolated dilated MPD’ (31/96, 63.3%, p=0.040) and ‘small duct disease’ (33/50, 66.0%, p=0.004). Guideline-concordant surgery (n=124, 66%) was not associated with major morbidity (concordant 12.9% vs discordant 18.8%, p=0.387), 90-day mortality (1.6% vs 1.6%, p>0.999), and pain relief (75.3% vs 66.7%, p=0.468). Guideline-based drainage/parenchyma preserving surgery was not associated with lower major morbidity (9.2% vs 18.9%, p=0.177) and mortality (0 vs 1.9%, p=0.449) vs formal pancreatectomy. The survey confirmed variability in the use of surgery per morphological subtype which may be related to conflicting recommendations (n=4) and the unclear role for formal pancreatectomy (e.g. pancreatoduodenectomy) and V-shaped pancreatectomy in current guidelines.Conclusion: The next generation of unified guidelines for surgery in symptomatic chronic pancreatitis should resolve the current conflicting recommendations and address the role of formal pancreatectomy and V-shaped pancreatectomy.

4 September 2026 in Annals of Surgery
Verified
Journal Article
Open access
CVCharlotte L. Van Veldhuisen
Charlotte L. Van Veldhuisen
CLCharlotte A. Leseman
Charlotte A. Leseman
FRFleur E.M. De Rijk
Fleur E.M. De Rijk
JMJoana C. Marques-Antunes
Joana C. Marques-Antunes
FAFabio Ausania
Fabio Ausania
MBMarc G. Besselink
Marc G. Besselink
Objective: To evaluate the use and impact of current surgical guidelines for chronic pancreatitis (CP) across Europe. Summary Background Data: Current guidelines recommend morphology-based surgery for CP, but international studies evaluating their use and impact are lacking. Methods: Post hoc analysis of the prospective multicenter ESCOPA study, including patients undergoing surgery for symptomatic CP at 22 centers in 13 countries (June 2021–November 2022), with 6-month follow-up. Patients were stratified by morphologic subtype: “isolated dilated main pancreatic duct (MPD),” “isolated enlarged pancreatic head (PH),” “combined dilated MPD and enlarged PH,” and “small duct disease.” Treatment was based on the European HaPanEU and International IAP-APA-JPS-EPC guidelines. Primary outcomes were 90-day major morbidity, mortality, and pain relief at 6 months. Practice variation was assessed, including a case-based survey. Results: Overall, 207 patients were included following surgery for CP, with 1.4% 90-day mortality and 72.6% pain relief. The surgical approach varied widely by morphologic subtype: duodenum-preserving pancreatic head resections (DPPHR) were most common for “combined dilated MPD and enlarged PH” (46.8%, P =0.016); whereas formal pancreatectomy predominated for “isolated dilated MPD” (63.3%, P =0.040) and “small duct disease” (66.0%, P =0.004). Guideline-concordant surgery (66%) was not associated with improved rates of major morbidity (12.9% vs. 18.8%, P =0.387), mortality (1.6% vs. 1.6%, P >0.999), or pain relief (75.3% vs. 66.7%, P =0.468). Outcomes were also comparable between drainage/parenchyma-preserving surgery and formal pancreatectomy. Survey findings confirmed practice variation, including the use of formal and V-shaped pancreatectomy for small duct disease. Conclusion: The substantial variation in surgical practice for CP across Europe highlights the need for unified guidelines with clear recommendations, particularly regarding formal and V-shaped pancreatectomy.